Company news from the 07/25/06 News Brief

Gilead Sciences has agreed to exercise its option to purchase Corus Pharma for $365 million. Gilead anticipates that the deal will close in the third quarter of 2006. Concurrently, Gilead and Novartis Vaccine and Diagnostics have entered into an agreement whereby Novartis has agreed to dismiss its ongoing litigation with Corus for an undisclosed payment.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions